Advertisement
"Kevin and Magnus are seasoned executives with global marketing andbusiness management experience with major international medical devicecompanies," said Bevil J. Hogg, Chief Executive Officer of Stereotaxis."Kevin brings more than 15 years of healthcare experience, and his expertisein medical devices, insight into product development and global marketing, andstrong connections with physicians worldwide will help us further strengthenour marketing capabilities. Magnus is a highly experienced veteran of theelectrophysiology lab and honed his skills with increasing responsibilities insales, clinical development, market development and business management atBiosense Webster. We believe they can add significant value and experience toour Company as we continue to expand our business, and continue to strengthenour major industry partnerships."
Advertisement
Mr. Shifrin, 42, joins Stereotaxis from C.R. Bard, a developer,manufacturer and marketer of healthcare products in the fields of vascular,urology, oncology and surgical specialty products, where he served as VicePresident of Global Marketing for the Peripheral Vascular Division. He joinedBard in 2002 from Cordis Corporation, a subsidiary of Johnson & Johnson, wherehe served as the Executive Director of Marketing for Cordis Cardiology Europe,and helped oversee the execution of European marketing programs supporting theCordis stent business. Prior to joining Cordis in 2002, he spent eight yearsat Bard in a variety of sales, marketing and product management positions withseveral divisions in the U.S., Europe, Asia, and Latin America.
"I look forward to leading Stereotaxis' global marketing efforts andbelieve the Company's unique and innovative magnetic navigation system setsthe standard of care for treatment of coronary disease and arrhythmiaworldwide," said Mr. Shifrin. "I joined Stereotaxis because I see thetremendous potential for the Niobe system and the Odyssey network, asphysicians are increasingly called upon to perform highly complexinterventional procedures safely and effectively."
Mr. Shifrin earned his MBA in Marketing from the University of ChicagoGraduate School of Business in 1991, and his B.S. with honors in PublicAdministration from the University of Southern California.
Dr. Holm, 44, joins Stereotaxis from Biosense Webster, a leader intechnological advancements for the diagnosis and treatment of cardiacarrhythmias, where he served most recently as Vice President of EMEA. In thiscapacity, Dr. Holm was responsible for sales and marketing and businessdevelopment throughout the EMEA region. Throughout his 10-year tenure at theJohnson & Johnson subsidiary, Dr. Holm held a variety of positions in marketand clinical development and business management.
"Stereotaxis is a growing company dedicated to providingelectrophysiologists and other specialists with a safe and effective state ofthe art system designed for very complex and difficult procedures," said Dr.Holm. "I believe Europe presents a tremendous growth opportunity as moreclinical studies are performed and additional EP labs adopt thesesophisticated, high-end cardiology solutions."
Prior to joining Biosense Webster in 1997, Dr. Holm spent six years as ahospital engineer and Ph
